{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:48:05Z","timestamp":1782172085499,"version":"3.54.5"},"reference-count":61,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Platelet transfusion refractoriness (PTR) represents a major challenge in the transfusion support of patients with severe thrombocytopenia, particularly those with hematologic malignancies, intensive chemotherapy, or hematopoietic stem cell transplantation. Although nonimmune mechanisms account for the majority of cases, immune-mediated PTR caused by alloantibodies against platelet antigens, most commonly human leukocyte antigen (HLA) class I molecules, remains clinically important. This review summarizes current knowledge on the definition, mechanisms, diagnostic evaluation, and management of immune PTR. The immunologic basis of platelet destruction in immune PTR involves several mechanisms mediated by anti-HLA antibodies, including Fc receptor-dependent phagocytosis, complement activation, and antibody-induced platelet activation. Diagnostic evaluation integrates clinical assessment with laboratory detection of HLA antibodies, molecular HLA typing, and platelet crossmatching. Clinical management primarily relies on the provision of compatible platelet products, including HLA-matched platelets, antibody-specific antigen-negative platelet units, or crossmatched platelet concentrates. In selected cases, additional testing for antibodies against human platelet antigens (HPAs) may be required. Preventive strategies such as leukoreduction have substantially reduced the incidence of alloimmunization, although immune PTR continues to occur in a subset of transfusion-dependent patients. Emerging strategies aimed at improving transfusion outcomes include approaches to reduce platelet immunogenicity, development of HLA-deficient platelets, and pharmacologic interventions targeting antibody-mediated platelet clearance. A better understanding of the mechanisms underlying immune PTR may help refine diagnostic algorithms and expand therapeutic options for patients requiring long-term platelet transfusion support.<\/jats:p>","DOI":"10.1055\/a-2887-8181","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:14:20Z","timestamp":1782170060000},"source":"Crossref","is-referenced-by-count":0,"title":["Diagnosis and Management of Immune Platelet Transfusion Refractoriness"],"prefix":"10.1055","author":[{"given":"Sara","family":"Reda","sequence":"additional","affiliation":[{"name":"University Hospital Cologne, Germany","place":["Cologne"],"department":["Institute of Transfusion Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0672-2453","authenticated-orcid":false,"given":"Heiko","family":"R\u00fchl","sequence":"additional","affiliation":[{"name":"University Hospital Bonn, Germany","place":["Bonn"],"department":["Institute for Experimental Hematology and Transfusion Medicine"]},{"name":"Saarland University, Germany","place":["Homburg"],"department":["Institute for Clinical Hemostaseology and Transfusion Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1182\/asheducation-2007.1.172","article-title":"Evidence-based platelet transfusion guidelines","author":"S J Slichter","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.47420\/9783769138078","volume-title":"Richtlinie Zur Gewinnung von Blut Und Blutbestandteilen Und Zur Anwendung von Blutprodukten (Richtlinie H\u00e4motherapie). Gesamtnovelle 2023","author":"Bundes\u00e4rztekammer","year":"2023"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/hematology.2020000137","article-title":"Platelet transfusion refractoriness: how do I diagnose and manage?","volume":"2020","author":"C S Cohn","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2003-08-2724","article-title":"Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients","volume":"105","author":"S J Slichter","year":"2005","journal-title":"Blood"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tmrv.2020.09.010","article-title":"Human leukocyte antigen Alloimmunization and Alloimmune platelet refractoriness","volume":"34","author":"A Saris","year":"2020","journal-title":"Transfus Med Rev"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/vox.12085","article-title":"Human platelet antigens \u2013 2013","volume":"106","author":"B R Curtis","year":"2014","journal-title":"Vox Sang"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3324\/haematol.2018.189365","article-title":"A subset of anti-HLA antibodies induces Fc\u03b3RIIa-dependent platelet activation","volume":"103","author":"M Rijkers","year":"2018","journal-title":"Haematologica"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3324\/haematol.2018.201665","article-title":"Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets","volume":"104","author":"M Rijkers","year":"2019","journal-title":"Haematologica"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.2830140407","article-title":"Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion","volume":"14","author":"D E Hogge","year":"1983","journal-title":"Am J Hematol"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1046\/j.1537-2995.1999.39060586.x","article-title":"Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution","volume":"39","author":"K B Davis","year":"1999","journal-title":"Transfusion"},{"key":"ref11","volume-title":"Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten","author":"Bundes\u00e4rztekammer","year":"2020"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2008.07189.x","article-title":"Platelet transfusion refractoriness","volume":"142","author":"E Hod","year":"2008","journal-title":"Br J Haematol"},{"issue":"26","key":"ref13","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJM199712253372601","article-title":"Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions","volume":"337","author":"Trial to Reduce Alloimmunization to Platelets Study Group","year":"1997","journal-title":"N Engl J Med"},{"issue":"20","key":"ref14","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1182\/blood.2023022883","article-title":"How I treat patients who are refractory to platelet transfusions","volume":"145","author":"S Nahirniak","year":"2025","journal-title":"Blood"},{"issue":"03","key":"ref15","first-page":"200","article-title":"Relative importance of immune and non-immune causes of platelet refractoriness","volume":"66","author":"H A Doughty","year":"1994","journal-title":"Vox Sang"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.tmrv.2020.09.002","article-title":"Non-Alloimmune mechanisms of thrombocytopenia and refractoriness to platelet transfusion","volume":"34","author":"R Belizaire","year":"2020","journal-title":"Transfus Med Rev"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/1096-8652(200008)64:4<251::AID-AJH3>3.0.CO;2-N","article-title":"Platelet transfusions: utilization and associated costs in a tertiary care hospital","volume":"64","author":"K R Meehan","year":"2000","journal-title":"Am J Hematol"},{"issue":"09","key":"ref18","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1537-2995.2008.01799.x","article-title":"The clinical impact of platelet refractoriness: correlation with bleeding and survival","volume":"48","author":"J L Kerkhoffs","year":"2008","journal-title":"Transfusion"},{"issue":"14","key":"ref19","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1002\/cam4.3140","article-title":"Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia","volume":"9","author":"X Hu","year":"2020","journal-title":"Cancer Med"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/trf.16398","article-title":"Platelet CD36 deficiency is present in 2.6% of Arabian individuals and can cause NAIT and platelet refractoriness","volume":"61","author":"B K Flesch","year":"2021","journal-title":"Transfusion"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood.V95.5.1735.005k47_1735_1742","article-title":"Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens","volume":"95","author":"K W Bang","year":"2000","journal-title":"Blood"},{"issue":"01","key":"ref22","first-page":"84","article-title":"Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension","volume":"9","author":"F H Claas","year":"1981","journal-title":"Exp Hematol"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2003-03-0940","article-title":"Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness","volume":"103","author":"M D Seftel","year":"2004","journal-title":"Blood"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1537-2995.2006.00913.x","article-title":"Platelet binding and phagocytosis by macrophages","volume":"46","author":"B A Badlou","year":"2006","journal-title":"Transfusion"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/MOH.0b013e32833e7561","article-title":"Novel clearance mechanisms of platelets","volume":"17","author":"R Grozovsky","year":"2010","journal-title":"Curr Opin Hematol"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.tmrv.2019.09.003","article-title":"Complement as an immune barrier in platelet transfusion refractoriness","volume":"33","author":"S Meinke","year":"2019","journal-title":"Transfus Med Rev"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/jth.15265","article-title":"Platelet Fc\u03b3RIIA in immunity and thrombosis: adaptive immunothrombosis","volume":"19","author":"P Patel","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.1991.tb04386.x","article-title":"Interaction of two GPIIb\/IIIa monoclonal antibodies with platelet Fc receptor (Fc gamma RII)","volume":"78","author":"E Rubinstein","year":"1991","journal-title":"Br J Haematol"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/trf.15737","article-title":"Frequency of CD36 deficiency in Thais analyzed by quantification of CD36 on cell surfaces and in plasma","volume":"60","author":"R Phuangtham","year":"2020","journal-title":"Transfusion"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2017-07-799270","article-title":"Platelets from donors with consistently low HLA-B8, -B12, or -B35 expression do not undergo antibody-mediated internalization","volume":"131","author":"A Saris","year":"2018","journal-title":"Blood"},{"issue":"16","key":"ref31","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1182\/blood-2012-12-472779","article-title":"Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants","volume":"121","author":"R P Jackman","year":"2013","journal-title":"Blood"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/bjh.12369","article-title":"The mean fluorescence intensities of anti-HLA antibodies detected using micro-bead flow cytometry predict the risk of platelet transfusion refractoriness","volume":"162","author":"A Beligaswatte","year":"2013","journal-title":"Br J Haematol"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ajcp\/aqy121","article-title":"HLA-mediated platelet refractoriness","volume":"151","author":"A E Schmidt","year":"2019","journal-title":"Am J Clin Pathol"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOT.0b013e32832d31c7","article-title":"Strategies for human leukocyte antigen antibody detection","volume":"14","author":"R A Bray","year":"2009","journal-title":"Curr Opin Organ Transplant"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/ajt.12287","article-title":"Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA","volume":"13","author":"E F Reed","year":"2013","journal-title":"Am J Transplant"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5858\/arpa.2023-0484-RA","article-title":"Advances in human leukocyte antigen testing technologies and management strategies for platelet transfusion refractoriness","volume":"149","author":"H C Sullivan","year":"2025","journal-title":"Arch Pathol Lab Med"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1744-313X.2011.01040.x","article-title":"Human leucocyte antigen typing: techniques and technology, a critical appraisal","volume":"38","author":"P P Dunn","year":"2011","journal-title":"Int J Immunogenet"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/trf.12395","article-title":"Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review","volume":"54","author":"R R Vassallo","year":"2014","journal-title":"Transfusion"},{"issue":"22","key":"ref39","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJM196911272812202","article-title":"Platelet transfusion therapy; the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing","volume":"281","author":"R A Yankee","year":"1969","journal-title":"N Engl J Med"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/trf.15108","article-title":"HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience","volume":"59","author":"C Karlstr\u00f6m","year":"2019","journal-title":"Transfusion"},{"issue":"05","key":"ref41","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/trf.15728","article-title":"Ensuring HLA-matched platelet support requires an ethnic diverse donor population","volume":"60","author":"A L Kreuger","year":"2020","journal-title":"Transfusion"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1537-2995.2007.01516.x","article-title":"Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support?","volume":"48","author":"R J Duquesnoy","year":"2008","journal-title":"Transfusion"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood.2020007199","article-title":"An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial","volume":"137","author":"J C Marsh","year":"2021","journal-title":"Blood"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1111\/trf.12175","article-title":"Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review","volume":"53","author":"K Pavenski","year":"2013","journal-title":"Transfusion"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1423-0410.1996.7120084.x","article-title":"Procoagulant effect of incompatible platelet transfusions in alloimmunized refractory patients","volume":"71","author":"R Mazzara","year":"1996","journal-title":"Vox Sang"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/trf.15664","article-title":"Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation","volume":"60","author":"K Seike","year":"2020","journal-title":"Transfusion"},{"issue":"07","key":"ref47","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.2025.7529","article-title":"Platelet transfusion: 2025 AABB and ICTMG international clinical practice guidelines","volume":"334","author":"R A Metcalf","year":"2025","journal-title":"JAMA"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0002-9343(87)90548-1","article-title":"Treatment of platelet alloimmunization with intravenous immunoglobulin. Two case reports and review of the literature","volume":"83","author":"J Kurtzberg","year":"1987","journal-title":"Am J Med"},{"issue":"02","key":"ref49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/09537104.2014.895922","article-title":"Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness","volume":"26","author":"J Cid","year":"2015","journal-title":"Platelets"},{"issue":"08","key":"ref50","first-page":"14080","article-title":"Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases","volume":"8","author":"W Liu","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"07","key":"ref51","first-page":"CD009072","article-title":"Pathogen-reduced platelets for the prevention of bleeding","volume":"7","author":"L J Estcourt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"06","key":"ref52","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3390\/pathogens11060639","article-title":"Efficacy and safety of pathogen-reduced platelets compared with standard apheresis platelets: a systematic review of RCTs","volume":"11","author":"I Pati","year":"2022","journal-title":"Pathogens"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1537-2995.1988.28188127942.x","article-title":"Selective elution of HLA antigens and beta 2-microglobulin from human platelets by chloroquine diphosphate","volume":"28","author":"K J Kao","year":"1988","journal-title":"Transfusion"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1423-0410.1989.tb00823.x","article-title":"New approach to eliminate HLA class I antigens from platelet surface without cell damage: acid treatment at pH 3.0","volume":"57","author":"Y Kurata","year":"1989","journal-title":"Vox Sang"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/trf.16282","article-title":"HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients","volume":"61","author":"M R Mirlashari","year":"2021","journal-title":"Transfusion"},{"issue":"02","key":"ref56","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/trf.13350","article-title":"Platelets made HLA deficient by acid treatment aggregate normally and escape destruction by complement and phagocytes in the presence of HLA antibodies","volume":"56","author":"S Meinke","year":"2016","journal-title":"Transfusion"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.stemcr.2019.11.011","article-title":"iPSC-derived platelets depleted of HLA class I are inert to anti-HLA class I and natural killer cell immunity","volume":"14","author":"D Suzuki","year":"2020","journal-title":"Stem Cell Rep"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2119\/molmed.2015.00235","article-title":"Generation of HLA-universal iPSC-derived megakaryocytes and platelets for survival under refractoriness conditions","volume":"22","author":"A K B\u00f6rger","year":"2016","journal-title":"Mol Med"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.16385","article-title":"A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen Allo-immunized patients","volume":"189","author":"P Vo","year":"2020","journal-title":"Br J Haematol"},{"issue":"16","key":"ref60","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2022016376","article-title":"Antigen-guided depletion of anti-HLA antibody-producing cells by HLA-fc fusion proteins","volume":"140","author":"A M Webber","year":"2022","journal-title":"Blood"},{"issue":"15","key":"ref61","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1182\/bloodadvances.2022007195","article-title":"Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies","volume":"6","author":"D R Lynch","year":"2022","journal-title":"Blood Adv"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2887-8181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:14:37Z","timestamp":1782170077000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2887-8181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":61,"URL":"https:\/\/doi.org\/10.1055\/a-2887-8181","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}